) is developing a novel monoclonal antibody, BL-9020, which
targets the Natural Killer (NK) receptor NKp46.
BioLineRx recently joined forces with JHL Biotech for the
development and commercialization of BL-9020 for the treatment of
type I diabetes.
As per the deal, JHL Biotech will have global manufacturing
rights to BL-9020 along with development and commercialization
rights in China and Southeast Asia, while BioLineRx will have
development and commercialization rights for the rest of the
world. Both the parties will be entitled to single-digit
royalties on the sale of BL-9020 in the other party's
We note that in Oct 2013, BioLineRx in-licensed BL-9020 from
Yissum Research Development Company of the Hebrew University of
Jerusalem, B.G. Negev Technologies and Applications Ltd., and
Hadasit Medical Research Services and Development Ltd.
In China roughly 100 million people are affected by diabetes.
By 2035, the number is expected to reach 150 million, thus making
China one of the largest diabetes markets in the world. Around
5-10% of diabetes cases are of the type I variant.
We are positive on the decision of BioLineRx to collaborate
with JHL Biotech. This deal makes sense, as it brings together
JHL Biotech's expertise in the development and manufacturing of
biologic products and BioLineRx' innovative technologies.
BioLineRx carries a Zacks Rank #3 (Hold). Other better-ranked
players in the pharma industry include
Sucampo Pharmaceuticals Inc.
PharmaTech (Cayman) Inc.
Jazz Pharmaceuticals Inc.
). All the three stocks carry a Zacks Rank #1 (Strong Buy).
BIOLINE RX LTD (BLRX): Get Free Report
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
SUCAMPO PHARMAC (SCMP): Free Stock Analysis
WUXI PHARMATECH (WX): Free Stock Analysis
To read this article on Zacks.com click here.